PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.
Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that its Board of Directors have put in place loan funding of $2.5m to extend the Company's funding runway for the development and licensing of its clinical assets.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4D financial report for the half year ending 31st December 2018.
Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will be presenting at the Proactive Investors Australia CEO Sessions and the Wholesale Investor's Emergence 2019 conferences this month.
This month, Anatara's CEO, Steve Lydeamore will be presenting to investors at events in Sydney and Melbourne. We would like to extend to you the invitation to attend.
